Onkologie. 2012:6(2):79-82

New options of expensive pneumo-oncological therapy for advanced non-small-cell lung carcinoma (NSCLC) in the

Jana Skřičková

Klinika nemocí plicních a tuberkulózy LF MU a FN Brno Bohunice

first line based on morphological and molecular genetic diagnosis in the Czech Republic

Current diagnosis of non-small-cell lung carcinoma (NSCLC) cannot rest merely on the determination that it is NSCLC without providing

any further specification. Accurate morphological classification of NSCLC and classification into individual subtypes (adenocarcinoma,

large-cell carcinoma, squamous-cell carcinoma…) as well as genetic testing are all required. When the morphological and molecular

genetic diagnosis has been accurately established, patients with NSCLC can receive agents whose efficacy, while meeting certain criteria,

offers a chance of improved survival. They include both drugs from the cytostatic group and those for biologically targeted therapy. The

paper deals with those agents for which the amount of reimbursement for the first-line treatment of NSCLC has been determined in the

Czech Republic. They are bevacizumab, pemetrexed and gefitinib.

Keywords: non-small-cell lung carcinoma (NSCLC), diagnosis, treatment of advanced NSCLC, biological therapy, pemetrexed

Published: April 23, 2012  Show citation